Search Results - engineered

6 Results

Sort By:

A Cell Line that Expresses secNluc and GFP to Recapitulate PMP22 Gene Expression for Studying Peripheral Neuropathy

This technology includes a cell line that expresses two reporters (a secreted luciferase, secNLuc, and GFP) in a pattern that recapitulates the endogenous expression of the peripheral myelin protein 22 (Pmp22) gene. Pmp22 is mainly expressed in the Schwann cells of the peripheral nervous system. Many neurological disorders are associated with aberrations...

Published: 7/25/2024 | Inventor(s): John Svaren, Sung-Wook Jang, James Inglese

Keywords(s): Cell, Coincidence, ENDOGENOUS, ENGINEERED, Express, Expression, Gene, GENETICALLY, GFP, Line, Listed LPM Tong as of 4/15/2015, LOCUS, Pmp22, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Recapitulate, Reporters, SecNluc, That, VEXXXX, WIXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, Application > Research Materials

Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals

This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of...

Published: 7/25/2024 | Inventor(s): Charles Rupprecht

Keywords(s): CDC Docket Import, CDC Docket Import NP, DC5BXX, DC5XXX, DCXXXX, Dogs, DXXXXX, ENGINEERED, GENETICALLY, Immunization, rabies, recombinant, Stray, Vaccine, VLXXXX, VOXXXX, WFXXXX, Wildlife, WJXXXX, WMXXXX, XEXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Occupational Safety and Health, Application > Therapeutics, Application > Vaccines, Application > Consumer Products

Engineered Anthrax Toxin Variants that Target Cancer

This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath

Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Cell-Nanofiber Composite and Cell-Nanofiber Composite Amalgam Based Engineered Intervertebral Disc

Diseased or damaged musculoskeletal tissues are often replaced by an artificial material, cadaver tissue or donated, allogenic tissue. Tissue engineering offers an attractive alternative whereby a live, natural tissue is generated from a construct made up of a patient’s own cells or an acceptable/compatible cell source in combination with a biodegradable...

Published: 8/12/2024 | Inventor(s): Rocky Tuan, Leon Nesti, Wan-Ju Li

Keywords(s): AB1XXX, AB3AXX, AB3CXX, AB3GXX, AB3XXX, ABXXXX, Amalgam, AXXXXX, Based, Cell-nanofiber, Composite, DISC, ENGINEERED, Intervertebra

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available

Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization

Scientists at the NIH disclosed a mutated adeno-associated virus (AAV) serotype 5 by modifying sialic acid binding regions which mediate viral entry into host cells. Preliminary results from animal studies suggest that this modification can increase transduction by 3-4 folds in salivary glands and muscles, and can significantly decrease the potential...

Published: 7/25/2024 | Inventor(s): Sandra Afione-Wainer, Mavis Agbandje-Mckenna, Sujata Halder, John (Jay) Chiorini

Keywords(s): AAV5, ANTIBODY, ENGINEERED, Enhanced, GENETICALLY, Listed LPM Reichman as of 4/15/2015, Neutralization, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REDUCED, transduction, VAXXXX, VCXXXX, vectors, VFXXXX, VGXXXX, WJXXXX, XEXXXX, YAXXXX, YCXXXX

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Geriatrics, TherapeuticArea > Endocrinology, TherapeuticArea > Oncology, Application > Therapeutics